Primary Progressive Multiple Sclerosis Treatment Market 2026 reaching $2.18 billion by 2030
The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
How Much Is The Primary Progressive Multiple Sclerosis (PPMS) Treatment Market Expected To Grow In Terms Of Market Value Between 2026 And 2030?
The market for primary progressive multiple sclerosis (ppms) treatments has experienced swift expansion recently. This market is projected to expand from $1.16 billion in 2025 to $1.31 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 13.7%. Historically, this growth can be ascribed to factors such as restricted treatment options for ppms, the dependence on corticosteroids for managing symptoms, inadequate patient awareness of ppms, an underdeveloped hospital pharmacy infrastructure, and the gradual uptake of immunosuppressants.
The primary progressive multiple sclerosis (ppms) treatment market is projected to expand significantly in the coming years, reaching $2.18 billion by 2030, driven by a compound annual growth rate (CAGR) of 13.5%. This anticipated expansion throughout the forecast period can be ascribed to several factors, including the emergence of targeted monoclonal antibodies, heightened research and development efforts in neurodegenerative conditions, the broadening of hospital and online pharmacy infrastructures, a surge in regulatory approvals for new treatments, and enhanced patient awareness and early detection initiatives. Key trends expected during this period involve an increasing uptake of monoclonal antibodies for ppms, a greater emphasis on managing symptoms and improving quality of life, a growing preference for intravenous drug delivery, the expansion of hospital and specialty pharmacy networks, and the creation of innovative therapeutics and combination treatments.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24670&type=smp
What Key Drivers Are Influencing The Growth Of The Primary Progressive Multiple Sclerosis (PPMS) Treatment Market?
The primary progressive multiple sclerosis (PPMS) treatment market is projected to grow in the future due to the increasing need for effective treatments. These treatments are medical interventions that lessen symptoms, improve patient results, or cure a disease or condition. The rising demand for effective treatments is primarily fueled by the increasing occurrence of chronic and complex health conditions, which necessitate sustained management and advanced therapeutic interventions to enhance patient outcomes and quality of life. Specifically for primary progressive multiple sclerosis (PPMS), effective treatments aid in slowing its advancement by targeting inflammation and maintaining neurological function, thereby enhancing long-term quality of life, minimizing disability buildup, and boosting patients’ capacity to manage daily activities with greater independence and stability. As an example, in January 2024, as reported by the American Society of Gene & Cell Therapy, a US-based organization for gene and cell therapy, the count of gene therapies in Phase III clinical trials reached 33 Phase III gene therapy trials in 2023, which was an increase of 10% compared to 2022, marking the first quarterly increase since Q3 2022. Consequently, the escalating demand for effective treatments propels the expansion of the primary progressive multiple sclerosis (PPMS) treatment market.
What Major Segment Divisions Exist Within The Primary Progressive Multiple Sclerosis (PPMS) Treatment Market?
The primary progressive multiple sclerosis (ppms) treatment market covered in this report is segmented –
1) By Drug Type: Monoclonal Antibodies, Immunosuppressants, Corticosteroids, Other Drug Types
2) By Route Of Administration: Oral, Intravenous, Other Route Of Administrations
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels
Subsegments:
1) By Monoclonal Antibodies: Ocrelizumab, Rituximab, Ofatumumab, Ublituximab
2) By Immunosuppressants: Methotrexate, Azathioprine, Mycophenolate Mofetil, Cyclophosphamide
3) By Corticosteroids: Methylprednisolone, Prednisone, Dexamethasone, Hydrocortisone
4) By Other Drug Types: Biotin, Ibudilast, Laquinimod, Idebenone
How Are Trends Shaping The Direction Of The Primary Progressive Multiple Sclerosis (PPMS) Treatment Market?
Leading companies in the primary progressive multiple sclerosis (PPMS) treatment market are focusing on creating advanced formulations, such as monoclonal antibody drugs, to improve multiple sclerosis therapy. A monoclonal antibody drug aids in multiple sclerosis by specifically targeting immune cells or proteins that initiate inflammation and harm the nervous system, thereby reducing disease activity and slowing the advancement of symptoms. For instance, in February 2024, Roche Pharma India, an India-based pharmaceutical company, introduced Ocrevus (ocrelizumab), a monoclonal antibody drug, for treating multiple sclerosis (MS) in India. Ocrevus is significant as the first and only approved disease-modifying therapy (DMT) for both relapsing-remitting multiple sclerosis (RRMS) and primary progressive multiple sclerosis (PPMS) in the country. The drug operates by targeting CD20-positive B cells, a type of immune cell involved in the abnormal immune response observed in MS. It is administered as a twice-yearly intravenous infusion for only two hours, providing patients with a more convenient and effective treatment alternative.
Which Companies Are Leading Innovation In The Primary Progressive Multiple Sclerosis (PPMS) Treatment Market?
Major companies operating in the primary progressive multiple sclerosis (ppms) treatment market are F. Hoffmann-La Roche Ltd., Biogen Inc., Novartis AG, Teva Pharmaceutical Industries Ltd., Acorda Therapeutics Inc., Apitope International N.V., Atara Biotherapeutics Inc., Kyverna Therapeutics Inc., Clene Inc., Mapi Pharma Ltd., Abata Therapeutics Inc., MediciNova Inc., MedDay Pharmaceuticals SAS, AB Science S.A., Immunic AG, BrainStorm Cell Therapeutics Inc., TG Therapeutics Inc., EMD Serono Inc. (Merck KGaA), Mitsubishi Tanabe Pharma Corporation, Sanofi Genzyme, Alexion Pharmaceuticals (AstraZeneca Rare Disease), Viela Bio (Horizon Therapeutics), Receptos (Celgene/Bristol-Myers Squibb), Forward Pharma A/S, InnoCare Pharma, NervGen Pharma Corp., Priovant Therapeutics, Tiziana Life Sciences, Reata Pharmaceuticals, Biohaven Pharmaceutical Holding Company, Anokion SA
Read the full primary progressive multiple sclerosis (ppms) treatment market report here:
Which Region Is Expected To Register The Fastest Growth In The Primary Progressive Multiple Sclerosis (PPMS) Treatment Market?
North America was the largest region in the primary progressive multiple sclerosis (PPMS) treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the primary progressive multiple sclerosis (ppms) treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Primary Progressive Multiple Sclerosis (PPMS) Treatment Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=24670&type=smp
Browse Through More Reports Similar to the Global Primary Progressive Multiple Sclerosis (PPMS) Treatment Market 2026, By The Business Research Company
Multiple Sclerosis Drugs Market Report 2026
https://www.thebusinessresearchcompany.com/report/multiple-sclerosis-drugs-global-market-report
Atherosclerosis Drugs Market Report 2026
https://www.thebusinessresearchcompany.com/report/atherosclerosis-drugs-global-market-report
Focal Segmental Glomerulosclerosis Drugs Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
